Evidence map›Paper›PMID 39976870›Full record

ReviewCurrent HIV/AIDS reports2025

Update on Vaccination Recommendations for Adults with HIV.

Fiona Gispen, Kristen M Marks

Abstract readReview
In one paragraph

Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fiona GispenDivision of Infectious Diseases, Weill Cornell Medicine, 525 East 68th St, New York, NY, 10065, USA.
Kristen M MarksDivision of Infectious Diseases, Weill Cornell Medicine, 525 East 68th St, New York, NY, 10065, USA. markskr@med.cornell.edu.

Funding

T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
National Institute of Allergy and Infectious Diseases T32 A107613NIAID NIH HHS T32 AI007613
6 · The paper itself

Abstract

purpose of reviewVaccination recommendations for people with HIV (PWH) differ from the general population given potential for diminished immune responses as well as increased risk for infection or more severe disease. This review highlights updated vaccine recommendations, summarizes available data informing use of vaccines, and identifies areas in need of additional study for adults with HIV. RECENT

findingsVaccine recommendations differ for PWH in terms of timing, dosing, and need to check for serological response. New vaccines are available and recommended for PWH for prevention of invasive pneumococcal disease, respiratory syncytial virus (RSV), COVID-19, mpox, and hepatitis B virus (HBV). People with HIV experience persistent immune dysfunction, characterized by chronic immune activation and increased susceptibility to certain infections. To optimize potential of vaccines to reduce infection and infection-associated malignancies in PWH, strategies to improve vaccine responses and reduce vaccine hesitancy are necessary. While newer adjuvants show promise in enhancing immunogenicity, key questions remain regarding the durability of vaccine-induced protection and the ideal timing and necessity of booster doses for many vaccines.

Indexed as

HIV InfectionsVaccinationVaccinesAdultHumansVaccinesHIVHuman Immunodeficiency VirusVaccinationVaccineVaccine recommendationsVaccine update

Identifiers

PMID39976870
PMCPMC12372409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.